Published in Med Care on July 01, 2011
Risk of hospitalization according to chemotherapy regimen in early-stage breast cancer. J Clin Oncol (2014) 1.62
Risk and consequences of chemotherapy-induced neutropenic complications in patients receiving daily filgrastim: the importance of duration of prophylaxis. BMC Health Serv Res (2014) 0.77
The use of granulocyte colony-stimulating factors in a Canadian outpatient setting. Curr Oncol (2014) 0.75
Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population. Support Care Cancer (2017) 0.75
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol (2006) 11.26
Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol (2011) 7.24
Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA (2012) 5.90
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer (2006) 5.03
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2012) 4.42
Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood (2008) 4.06
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol (2007) 4.06
American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol (2013) 4.03
Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer (2006) 3.86
Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol (2012) 3.63
Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer (2007) 3.27
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer (2004) 3.15
Understanding biased selection in Medicare HMOs. Health Serv Res (2003) 2.83
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76
NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw (2011) 2.73
Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. J Clin Oncol (2012) 2.72
Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer (2011) 2.67
Economic analysis of targeting chemotherapy using a 21-gene RT-PCR assay in lymph-node-negative, estrogen-receptor-positive, early-stage breast cancer. Am J Manag Care (2005) 2.37
Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med (2005) 2.25
Cost-effectiveness of a home-based environmental intervention for inner-city children with asthma. J Allergy Clin Immunol (2005) 2.22
Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer (2005) 2.20
Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapy. J Clin Oncol (2006) 2.17
Translating research into evidence-based practice: the National Cancer Institute Community Clinical Oncology Program. Cancer (2010) 2.15
Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol (2005) 2.13
The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion (2007) 2.12
Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol (2006) 2.03
Assisted living and nursing homes: apples and oranges? Gerontologist (2003) 2.03
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol (2012) 2.02
Social and racial differences in selection of breast cancer adjuvant chemotherapy regimens. J Clin Oncol (2007) 1.92
Longevity and health care expenditures: the real reasons older people spend more. J Gerontol B Psychol Sci Soc Sci (2003) 1.87
Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med (2008) 1.85
Impact of distance to a urologist on early diagnosis of prostate cancer among black and white patients. J Urol (2012) 1.81
American Society of Clinical Oncology clinical practice guidelines: opportunities and challenges. J Clin Oncol (2008) 1.75
Increasing incidence of oral tongue squamous cell carcinoma in young white women, age 18 to 44 years. J Clin Oncol (2011) 1.68
Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res (2010) 1.66
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw (2008) 1.65
How good is assisted living? Findings and implications from an outcomes study. J Gerontol B Psychol Sci Soc Sci (2005) 1.63
Effectiveness of preventive dental treatments by physicians for young Medicaid enrollees. Pediatrics (2011) 1.63
Comparative effectiveness of intensity-modulated radiotherapy and conventional conformal radiotherapy in the treatment of prostate cancer after radical prostatectomy. JAMA Intern Med (2013) 1.60
Effect of early preventive dental visits on subsequent dental treatment and expenditures. Med Care (2012) 1.59
Receipt of National Comprehensive Cancer Network guideline-concordant prostate cancer care among African American and Caucasian American men in North Carolina. Cancer (2013) 1.56
Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol (2012) 1.56
A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer (2007) 1.54
Medicare prospective payment and quality of care for long-stay nursing facility residents. Med Care (2006) 1.52
The staffing-outcomes relationship in nursing homes. Health Serv Res (2008) 1.47
Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer. Cancer (2014) 1.40
Comparative effectiveness of oxaliplatin vs non-oxaliplatin-containing adjuvant chemotherapy for stage III colon cancer. J Natl Cancer Inst (2012) 1.39
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care (2008) 1.39
Cost-effectiveness of electrocardiography vs. electrocardiography plus limited echocardiography to diagnose LVH in young, newly identified, hypertensives. Am J Hypertens (2010) 1.39
Retracted Issues and early evidence for the economic evaluation of the effects of periodontal therapy on pregnancy outcomes. J Periodontol (2008) 1.38
Racial differences in clinical progression among Medicare recipients after treatment for localized prostate cancer (United States). Cancer Causes Control (2006) 1.38
Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol (2005) 1.38
How a North Carolina program boosted preventive oral health services for low-income children. Health Aff (Millwood) (2010) 1.36
Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007. Radiology (2013) 1.30
Retirement and physical activity: analyses by occupation and wealth. Am J Prev Med (2009) 1.28
Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol (2008) 1.27
Cost-effectiveness of the children's oncology group long-term follow-up screening guidelines for childhood cancer survivors at risk for treatment-related heart failure. Ann Intern Med (2014) 1.27
Proportion of physicians in large group practices continued to grow in 2009-11. Health Aff (Millwood) (2013) 1.27
Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat (2006) 1.25
Do Medicare HMOs still reduce health services use after controlling for selection bias? Health Econ (2002) 1.23
Undertreatment of cancer patients with chemotherapy is a global concern. J Oncol Pract (2008) 1.23
Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 1.23
Weight and wages: fat versus lean paychecks. Health Econ (2009) 1.21
Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol (2009) 1.21
Building community capacity to participate in cancer prevention research. Cancer Control (2006) 1.20
Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer (2007) 1.17
Chemotherapy-induced alopecia: psychosocial impact and therapeutic approaches. Support Care Cancer (2004) 1.16
Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health (2008) 1.14
Biosimilars: are they ready for primetime in the United States? J Natl Compr Canc Netw (2011) 1.14
Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trials. J Natl Compr Canc Netw (2003) 1.14
Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer. Breast Cancer Res Treat (2011) 1.13
Myeloid growth factors. J Natl Compr Canc Netw (2013) 1.13
American Society of Clinical Oncology Clinical Practice Guidelines: formal systematic review-based consensus methodology. J Clin Oncol (2012) 1.12
Race, healthcare access and physician trust among prostate cancer patients. Cancer Causes Control (2009) 1.12
Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis. J Clin Oncol (2011) 1.12
Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer (2007) 1.11
Why using current medications to select a medicare Part D plan may lead to higher out-of-pocket payments. Med Care Res Rev (2007) 1.11
Adapting clinical trials networks to promote cancer prevention and control research. Cancer (2006) 1.10
ASCO Clinical Practice Guidelines: Past, Present and Future. J Oncol Pract (2008) 1.10
Breast MRI utilization in older patients with newly diagnosed breast cancer. J Surg Res (2011) 1.08
The effect of hospital and surgeon volume on racial differences in recurrence-free survival after radical prostatectomy. Med Care (2008) 1.07
Medicare payment changes and nursing home quality: effects on long-stay residents. Int J Health Care Finance Econ (2006) 1.07
Costs associated with febrile neutropenia in the US. Pharmacoeconomics (2012) 1.06
Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis. Cancer (2012) 1.05
Effects of state minimum staffing standards on nursing home staffing and quality of care. Health Serv Res (2008) 1.05
Calendar time-specific propensity scores and comparative effectiveness research for stage III colon cancer chemotherapy. Pharmacoepidemiol Drug Saf (2013) 1.05
Predictors of reduced relative dose intensity and its relationship to mortality in women receiving multi-agent chemotherapy for epithelial ovarian cancer. Gynecol Oncol (2012) 1.04
Myeloid growth factors. J Natl Compr Canc Netw (2011) 1.03
Rationale, design, and sample characteristics of a practical randomized trial to assess a weight loss intervention for low-income women: the Weight-Wise II Program. Contemp Clin Trials (2011) 1.03
Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study. Cancer Med (2014) 1.03
Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer. Genet Med (2012) 1.03
Antiemetics: american society of clinical oncology clinical practice guideline update. J Oncol Pract (2011) 1.02
Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer (2009) 1.02
Use and timeliness of radiation therapy after breast-conserving surgery in low-income women with early-stage breast cancer. Cancer Invest (2012) 1.00